Commercial DevelopmentSignificant strides in commercialization with three commercialized assets and plans to expand the commercial team to 500+ employees.

Financial PerformanceKelun-Biotech reported strong financial results, driven by milestone payments from global collaborations and the progression of its innovative pipeline.

InnovationKelun-Biotech is advancing a multi-pronged ADC strategy across oncology and non-oncology, leveraging novel payloads, bispecific ADCs, and next-generation conjugation technologies.

Strategic PartnershipsLicensing and collaboration agreements contributed RMB 1.86bn revenue, reflecting strong partnerships, particularly milestone payments from MSD.

Bears Say

Market CompetitionThe TSLP-targeted therapy space continues to see active transactions, indicating growing momentum and potential competition in this area.

Operational CostsThe Company narrowed its net loss significantly to RMB 266.8mn, an improvement from RMB 574.1mn, but the net loss remains a concern as revenue growth outpaced cost expansion.

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

1.00%

Mutual Funds

― Other Institutional Investors

97.98% Public Companies and

Individual Investors

Detailed Ownership Overview >

6990 FAQ

What was Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s price range in the past 12 months?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H lowest stock price was HK$120.20 and its highest was HK$380.00 in the past 12 months.

What is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s market cap?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s market cap is HK$76.25B.

When is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s upcoming earnings report date?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s upcoming earnings report date is Sep 01, 2025 which is in 63 days.

How were Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s earnings last quarter?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H released its earnings results on Mar 24, 2025. The company reported -HK$2.641 earnings per share for the quarter, beating the consensus estimate of -HK$2.748 by HK$0.107.

Is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H overvalued?

According to Wall Street analysts Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H pay dividends?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H does not currently pay dividends.

What is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s EPS estimate?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s EPS estimate is -0.65.

How many shares outstanding does Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H have?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has 162,769,970 shares outstanding.

What happened to Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s price movement after its last earnings report?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H reported an EPS of -HK$2.641 in its last earnings report, beating expectations of -HK$2.748. Following the earnings report the stock price went up 0.231%.

Which hedge fund is a major shareholder of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H?

Currently, no hedge funds are holding shares in HK:6990